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Abstract  21 
Objective 22 
To compare the efficacy of topical non-steroidal anti-inflammatory drugs 23 
(NSAIDs) with topical capsaicin for pain relief in osteoarthritis (OA).  24 
Design 25 
A systematic literature search was conducted for randomised controlled trials 26 
(RCTs) examining any topical NSAID or capsaicin in OA. Pain relief at or nearest 27 
to four weeks was pooled using a random-effects network meta-analysis (NMA) 28 
in a Frequentist and Bayesian setting. Analysis was conducted for all trials and 29 
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for trials using drugs listed as licenced for OA in the British National Formulary 1 
(BNF).  2 
Results 3 
The trial network comprised 28 RCTs (7372 participants), of which 17 RCTs 4 
(3174 participants) were included in the as licensed analyses. No RCTs directly 5 
compared topical NSAIDs with capsaicin. Placebo was the only common 6 
comparator for topical NSAIDs and capsaicin. Frequentist and Bayesian effect 7 
size (ES) estimates were in agreement. Topical NSAIDs were statistically 8 
superior to placebo overall (ES 0.30, 95% confidence interval [CI] 0.19 to 0.41) 9 
and as licensed (ES 0.32, 95% CI 0.24 to 0.39). However, capsaicin was only 10 
statistically superior to placebo when used at licensed doses (ES 0.41, 95% CI 11 
0.17 to 0.64). No significant differences were observed in pain relief between 12 
topical NSAIDs and capsaicin (overall: ES 0.04, 95% CI -0.26 to 0.33; as 13 
licensed: ES-0.09, 95% CI -0.34 to 0.16).  14 
Conclusions  15 
Current evidence indicates that topical NSAIDs and capsaicin in licensed doses 16 
may be equally effective for pain relief in OA. Whether the equivalence varies 17 
between individuals remains unknown.  18 
Systematic review registration number 19 
2016:CRD42016035254 20 
Keywords 21 
Osteoarthritis, topical, capsaicin, non-steroidal anti-inflammatory drugs 22 
(NSAIDs), network, meta-analysis 23 
Running headline 24 
Topical NSAIDs and capsaicin in OA 25 
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Introduction 1 
Osteoarthritis (OA) is a major cause of pain and disability for which two topical 2 
treatments are used: non-steroidal anti-inflammatory drugs (NSAIDs) and capsaicin1-5. 3 
Topical NSAIDs, such as ibuprofen and diclofenac, reversibly block the production of 4 
prostanoids, thereby reducing pain and inflammation6. Topical NSAIDs, alongside 5 
paracetamol, are recommended by the National Institute of Health and Care Excellence 6 
(NICE) as first line pharmacological treatments1. Over £32 million’s worth of 7 
prescriptions of topical NSAIDs were dispensed in community pharmacies in England in 8 
20167. Topical NSAIDs are also freely available over-the-counter and are widely 9 
advertised to consumers. Meanwhile, capsaicin, the substance responsible for the 10 
warming spiciness of chili peppers, is primarily available on prescription in the UK. 11 
Almost 200,000 tubes of 0.025% capsaicin were dispensed in 2016, amounting to over 12 
£4 million7. Capsaicin is thought to cause defunctionalisation of spontaneously active 13 
peripheral nociceptors that otherwise maintain chronic pain conditions8. 14 
Topical NSAIDs and capsaicin are applied directly to the skin over the painful joint and 15 
little to no active drug is absorbed into the bloodstream, resulting in their favourable 16 
safety profiles8-10. Topical administration therefore offers a safe and effective alternative 17 
to oral analgesics for people with just one or a few painful peripheral joints, especially 18 
for individuals with comorbidities, multiple medications, or those wishing to avoid 19 
tablets. The efficacy of topical NSAIDs and capsaicin in OA is documented6, 11-14, 20 
however, no evidence for their relative efficacy is available so far to guide clinicians’ 21 
prescribing practice. We therefore undertook the present network meta-analysis (NMA) 22 
to compare topical NSAIDs with capsaicin in people with symptomatic OA.  23 
Method 24 
Protocol and registration 25 
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This work forms part of a project examining the relative efficacy of topical NSAIDs and 1 
capsaicin in OA and neuropathic pain. The protocol is published15 and is also available on 2 
PROSPERO (2016:CRD42016035254).  3 
Eligibility criteria 4 
Randomised controlled trials (RCTs) comparing any topical NSAID or capsaicin to placebo 5 
in participants with OA were included. No other comparators were included for this 6 
analysis and only placebo-controlled trials were examined. Participants with painful 7 
physician-diagnosed OA (clinical or radiographic) or chronic joint pain attributable to OA 8 
at any site (excluding the spine) were included. Spinal pain was excluded as it is difficult 9 
to differentiate between OA pain and back pain secondary to other aetiologies. Trials 10 
with pain due to multiple conditions were included if the data for OA could be extracted 11 
separately.  12 
Trials had to be a minimum of one week duration and report pain outcomes. Full texts 13 
published in any language and at any date were considered.  14 
Identification and selection of trials 15 
A search strategy, based on terms for (1) RCTs; (2) topical administration; (3) OA; and 16 
(4) capsaicin or NSAIDs, was created (Supplementary Information).  17 
Medline, Embase, Allied and Complementary Medicine Database (AMED), Cumulative 18 
Index for Nursing and Allied Health Literature (CINAHL), Web of Science, and Cochrane 19 
library were searched up to 16/11/2015. The searches were updated on 10/01/2018. In 20 
addition, reference lists of included publications and meta-analyses in the area were 21 
searched for eligible trials.  22 
Citations were exported to Endnote where duplicates were removed before titles, 23 
abstracts, and full texts were assessed for eligibility. 24 
Data collection and data items 25 
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The data were extracted independently by two authors (MSMP and JS) using a data 1 
extraction form created for this project. Publications in languages other than English 2 
were extracted by colleagues fluent in the language or using the Google Translate 3 
smartphone application. The following data were sought: 4 
• Publication details: Author, journal, year 5 
• Trial details: Country of study, trial funder, study design, blinding, setting, 6 
duration 7 
• Participant details: Number of participants and withdrawals, age, gender 8 
distributions, body mass index, joint affected, method of diagnosing OA 9 
• Intervention/placebo detail: Drug, formulation, dose/concentrations, frequency of 10 
application 11 
• Endpoint: Pain scores 12 
The primary end point was pain at or nearest to four weeks. Change from baseline pain 13 
scores (extracted or calculated) were used. If unavailable, endpoint pain scores or 14 
percent change from baseline were used. If pain was measured by more than one 15 
instrument in a study, the following hierarchy16-18 was used to extract pain outcome 16 
data: (1) visual analogue scale (VAS) global pain score; (2) categorical global pain 17 
score; (3) pain during activity, such as walking; (4) Western Ontario and McMaster 18 
Universities Osteoarthritis Index (WOMAC) pain subscale or pain subscale of other 19 
disease-specific composite tools; (5) Short Form-36  (SF-36) bodily pain subscale; (6) 20 
Health Assessment Questionnaire (HAQ) pain subscale, McGill pain questionnaire; (7) 21 
tenderness; (8) physician’s assessment of pain. Where multiple concentrations of a 22 
study drug were examined within a study, they were combined as one prior to the effect 23 
size (ES) calculations for the overall analyses19.  24 
Network structure 25 
A network diagram was plotted to illustrate the treatment nodes, direct comparisons, 26 
and indirect comparisons within the NMA. 27 
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Risk of bias within and across studies 1 
Risk of bias assessment was carried out independently by two authors (MSMP and JS) 2 
using a modified Cochrane Risk of Bias tool (Supplementary Material).  3 
Statistical analysis 4 
Hedges’ ES and corresponding standard error (SE) were calculated for each study. The 5 
estimates were combined using Frequentist and Bayesian random-effects NMAs. The 6 
Frequentist ES and associated 95% confidence interval (CI) were calculated. A Bayesian 7 
NMA was conducted using Markov chain Monte Carlo (MCMC) simulations. Non-8 
informative prior distributions were set, normal likelihood distributions were assumed, 9 
and three Markov chains with different initial values (chosen arbitrarily) were run 10 
simultaneously. The model fit was deemed appropriate, the chain converged within 11 
10,000 simulations, and a total of 20,000 simulations comprised the burn-in period. The 12 
subsequent 50,000 iterations were examined. The median and the 2.5th and 97.5th 13 
percentiles of the posterior distribution comprised the Bayesian ES and credible interval 14 
(CrI). The probability of each treatment being the best were calculated. 15 
An overall analysis was conducted using all drug concentrations and topical formulations. 16 
Subgroup analysis was then conducted to examine topical NSAIDs and capsaicin used as 17 
recommended in the British National Formulary (BNF)20 (Supplementary material). Trials 18 
were excluded from the as licensed analysis if they examined (1) topical NSAIDs not 19 
recommended in the BNF; (2) drugs used at concentrations lower than recommended; or 20 
(3) licenced drugs in formulations not in the recommended list. The as licensed analysis 21 
was conducted to guide clinical practice and inform decision-making based on the 22 
medications currently available to physicians.  23 
The frequentist NMA was conducted in Stata (StataCorp. 2015. Stata Statistical 24 
Software: Release 15. College Station, TX: StataCorp LP) using the “network” command 25 
21. The Bayesian analyses were conducted in WinBUGs software (version 1.4.3, MRS 26 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5 
 
Biostatistics Unit UK, 2007) using methods supplied by the NICE Decision Support Unit 1 
22. 2 
Results 3 
Study description 4 
The results of the literature search and reasons for exclusion from this meta-analysis are 5 
illustrated in Figure 1. Topical NSAIDs were compared to placebo in 32 RCTs. Data were 6 
not available for extraction for nine of the studies 23-31 and the remaining 23 studies 7 
(6957 participants) 32-54 were included in the NMA. Of these, 13 trials 34, 35, 37-42, 44, 46, 50, 8 
52, 53 used a topical NSAID at its recommended dose/formulation and were included in 9 
the as licensed analysis. Six placebo-controlled RCTs examining capsaicin were 10 
identified, of which five (415 participants) 55-59 were included in the NMA. Data from the 11 
sixth study60 were not available for extraction. Four trials 56-59 used 0.025% capsaicin 12 
four times per day, as recommended in the BNF.  13 
All trials were described as double-blinded and all but one55 were of parallel design. Data 14 
from the first period were extracted for the crossover trial. One publication was in 15 
Korean48 and the remainder were in English. 24 trials were limited to participants with 16 
knee OA, two to hand OA34, 57, and the two remaining trials56, 58 included OA at multiple 17 
sites (hand, wrist, elbow, shoulder, hip, knee, and ankle OA). 18 
Risk of bias  19 
Trials were associated with considerable risks of bias (Figure 2). Although described as 20 
randomised, only 20 publications described the method of random number sequence 21 
generation in sufficient detail to ascertain its risk of bias. Furthermore, only 13 of the 22 
included trials adequately described the methods of allocation concealment. Although 23 
described as double-blinded, this was only considered adequate in 60-65% of all trials. 24 
No capsaicin trials were deemed to adequately blind their participants due to the 25 
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warming sensation experienced on its initial application. Across the body of evidence, 1 
only six of the 28 studies analysed all participants that were randomised at baseline. 2 
Network meta-analysis 3 
Overall analysis 4 
The trial network was comprised of 28 RCTs with 3473 participants on placebo (28 5 
RCTs), 3693 on topical NSAIDs (23 RCTs), and 206 on capsaicin (5 RCTs) (Figure 3). 6 
Direct evidence for topical NSAIDs vs placebo and capsaicin versus placebo were 7 
available from placebo-controlled trials. No trials directly compared topical NSAIDs to 8 
capsaicin, and the two treatments were therefore compared using placebo as a common 9 
comparator (indirect evidence). 10 
Frequentist and Bayesian analyses were in agreement with identical ES and only minor 11 
differences in the CI versus CrI (Table 1). Direct estimates indicated that topical NSAIDs 12 
were superior to placebo for pain relief. In contrast, the ES estimate between capsaicin 13 
and placebo was associated with considerable variability and did not reach statistical 14 
significance. However, the indirect analyses found no statistically significant differences 15 
between topical NSAIDs and capsaicin, although the ES favoured topical NSAIDs. Topical 16 
NSAIDs had the highest probability of being the best treatment, followed by capsaicin 17 
and then placebo (Table 2).  18 
As licensed analysis 19 
Topical NSAIDs and capsaicin were used as licensed in 17 RCTs. 1705 participants on 20 
placebo (17 RCTs), 1328 on topical NSAID (13 RCTs), and 141 on capsaicin (4 RCTs) 21 
were included in the as licensed NMA. The results are presented in Table 1. Exclusion of 22 
non-licensed topical NSAIDs marginally raised the ES and it remained superior to 23 
placebo. In contrast, capsaicin at its licensed dose had a considerably increased ES that 24 
was statistically superior to placebo. Using placebo as a common comparator, no 25 
statistically significant differences remained between topical NSAIDs and capsaicin used 26 
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as licensed. However, the ES favoured capsaicin, which also had the highest probability 1 
of being the best treatment, followed by topical NSAIDs and placebo (Table 2).  2 
Discussion 3 
Current evidence indicates that topical NSAIDs and capsaicin, when used as licensed, are 4 
both superior to placebo for pain relief. No significant differences were identified in the 5 
level of pain relief offered by topical NSAIDs compared to capsaicin. However, limited 6 
and poor quality evidence for capsaicin in OA provides uncertainty. Displaying seemingly 7 
negligible differences in efficacy, the decision of whether to prescribe topical NSAIDs or 8 
capsaicin should be guided by patient preference, safety, costs, and subsequent 9 
individual patient response.  10 
Focusing on licensed doses of these two drugs renders the results of this meta-analysis 11 
more relevant for clinicians as they relate directly to the drugs recommended for 12 
prescription. The list of approved drugs was extracted from the BNF, a resource 13 
commonly used to guide prescribing practice in the UK61. The BNF was chosen as the 14 
leading authority on clinicians’ selection of medicines in the UK, however it should be 15 
noted that they offer only recommendations of licenced medications and physicians can 16 
prescribe medications outside the recommended list61.  17 
No direct or indirect (via NMA) quantitative evidence of the relative efficacy of topical 18 
NSAIDs versus capsaicin has been published previously. Some guidelines, such as those 19 
by Osteoarthritis Research Society International (OARSI) and European League Against 20 
Rheumatism (EULAR), provide equal recommendations for the two treatments2, 4, 5. This 21 
may indicate a perceived equivalence in efficacy, in line with the findings of the current 22 
meta-analysis. In contrast, a narrative review examining topical treatments in OA 23 
concluded that capsaicin had less efficacy than topical NSAIDs62. Similarly, topical 24 
NSAIDs are generally favoured in guidelines such as those by NICE and the American 25 
College of Rheumatology (ACR), perhaps indicating a postulated greater efficacy for 26 
topical NSAIDs1, 3. In addition, OARSI guidelines granted topical NSAIDs a greater mean 27 
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benefit score (6.0/10) versus capsaicin (5.1/10)2. However, the comparative efficacy of 1 
the treatments in the narrative review was concluded primarily based on their 2 
mechanism of action, rather than quantitative analysis. Capsaicin was thought to be less 3 
effective as it lacked significant tissue penetration and anti-inflammatory effects62. 4 
Furthermore, guideline decisions are based not only on perceived efficacy, but on the 5 
quality of evidence. Indeed, the preference of topical NSAIDs may reflect a greater 6 
confidence in the evidence, rather than a perception of a larger effect. This is in keeping 7 
with the wide confidence interval and associated uncertainty in the true effect of 8 
capsaicin in the current meta-analysis. 9 
Although pain in OA has traditionally been viewed as nociceptive in nature, it is now 10 
widely accepted that some people experience pain with neuropathic-like pain 11 
components. Pain descriptors indicative of neuropathic pain, such as “burning” and 12 
“shooting” pain are used by subsets of individuals with OA 63. In fact, almost 15% of 13 
people with knee pain report neuropathic-like pain64. This subgroup is of importance as 14 
true neuropathic pain is often difficult to manage and commonly does not respond to 15 
traditional analgesics, such as NSAIDs65, 66. Capsaicin, however, is licensed and used in 16 
neuropathic pain, where it is effective at higher doses67. It may therefore be that 17 
individuals with predominantly nociceptive OA pain benefit from topical NSAIDs whilst 18 
those with neuropathic pain components may benefit more from topical capsaicin. 19 
Further evidence on pain phenotypes and response to these two commonly used topical 20 
analgesics is warranted. 21 
The present meta-analysis is subject to several limitations. Firstly, the conclusions drawn 22 
are limited by the scarcity of data available on capsaicin in OA. Only four trials compare 23 
0.025% capsaicin to placebo and no direct estimates were available to compare topical 24 
NSAIDs to capsaicin. The low number of studies and participants on capsaicin resulted in 25 
an estimate with much uncertainty. The equivalence of the drugs may therefore be an 26 
artefact of the wide confidence intervals. Secondly, the probability of being the best 27 
treatment is based predominantly on the ES, not on the uncertainty of the estimate. The 28 
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probability of being the best was chosen to facilitate the translation of results to clinical 1 
practice, however the results should be interpreted with caution and in conjunction with 2 
the ES estimates. Thirdly, risk of bias assessment identified concerns over the high risk 3 
of bias in included trials. Poor compliance with complete outcome data reporting, 4 
analysis of all randomised participants, and pre-specification of published outcomes all 5 
have the potential to overestimate the results of this meta-analysis. Fourthly, because 6 
capsaicin is associated with a warming sensation on application, making it difficult to 7 
blind, it was deemed a high risk of bias domain for all capsaicin trials. This may results in 8 
inherent differences in the placebo group across the trial network, threatening the 9 
assumption of transitivity. Furthermore, the efficacy data for topical NSAIDs is 10 
predominantly based on knee OA (22 of 23 studies), whilst the trial population for 11 
capsaicin included hand, wrist, elbow, shoulder, hip, knee, and ankle OA. The differences 12 
in study populations may limit comparisons between the two treatments, however, it 13 
was not possible to conduct subgroup analyses by joint type due to limited data. Finally, 14 
by the very nature of analyses conducted at trial-level, the results of this NMA relate to 15 
populations of individuals with OA and may not be reflected at the individual patient 16 
level. In addition, data were unavailable to examine the efficacy of topical NSAIDs and 17 
capsaicin in subgroups with differing OA phenotypes (e.g. nociceptive versus 18 
neuropathic-like pain). Studies at the individual patient level are still required. 19 
In conclusion, current evidence indicates that topical NSAIDs and capsaicin offer similar 20 
levels of pain relief in OA. Larger and better conducted RCTs, particularly for capsaicin, 21 
are required to confirm this. However, it is unknown whether individuals with different 22 
pain phenotypes respond differently to these two commonly used topical analgesics.  23 
Further work on phenotypic features of OA pain and their response to these two drugs is 24 
warranted.   25 
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Figure legends 1 
Figure 1 - PRISMA flow diagram. Results of the systematic literature search for placebo-2 
controlled trials of topical NSAIDs and capsaicin in OA 3 
Figure 2 – Risk of bias assessment. Risk of bias scores for all studies included in the 4 
overall analysis.  5 
Figure 3 – Trial network diagram. Nodes (circles) are weighted to represent the number 6 
of participants using each intervention. The solid lines represent the direct comparisons 7 
of the treatments in RCTs. The dotted line represents indirect comparisons generated 8 
through the NMA. The lines are weighted to represent the number of comparisons 9 
 10 
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 Table 1 – Effect size (ES) and Frequentist confidence interval (CI)/Bayesian credible interval (CrI). Results of the overall and 
as licensed subgroup analysis of topical NSAIDs and capsaicin in OA. 
 
 
 
 
 
 
 
 
 
Comparison Type  
 Frequentist Bayesian 
N ES CI ES  CrI 
All trials 
Topical NSAID vs placebo  Direct 23 0.30 0.19 to 0.41 0.30 0.19 to 0.43 
Capsaicin vs placebo Direct 5 0.27 -0.01 to 0.54 0.27 -0.02 to 0.56 
Topical NSAIDs vs capsaicin  Indirect 28 0.04 -0.26 to 0.33 0.04 -0.28 to 0.35 
As licensed        
Topical NSAID vs placebo  Direct 13 0.32 0.24 to 0.39 0.32 0.24 to 0.42 
Capsaicin vs placebo Direct 4 0.41 0.17 to 0.64 0.41 0.16 to 0.66 
Topical NSAIDs vs capsaicin  Indirect 17 -0.09 -0.34 to 0.16 -0.09 -0.35 to 0.18 
ES: effect size, CI: confidence interval, CrI: credible interval, N: number of studies 
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Table 2 – Treatment rankings. The probability of each treatment being the “best” 
using Frequentist and Bayesian approaches 
 
 
 
 
 Probability of being the best (%) 
 Frequentist  Bayesian 
All trials   
Topical NSAID 61.9 58.9 
Capsaicin 38.1 41.1 
Placebo 0.0 0.0 
As licensed   
Topical NSAID 23.5 25.9 
Capsaicin 76.5 74.1 
Placebo 0.0 0.0 
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